Rocket Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Selling, General & Admin	101.96	70.32	58.77	41.77	28.87	Upgrade
Research & Development	171.24	186.34	165.07	124.48	105.44	Upgrade
Operating Expenses	273.21	256.66	223.84	166.25	134.3	Upgrade
Operating Income	-273.21	-256.66	-223.84	-166.25	-134.3	Upgrade
Interest Expense	-1.89	-1.88	-1.86	-2.98	-6.97	Upgrade
Interest & Investment Income	8.27	5.29	3.89	3.07	2.15	Upgrade
EBT Excluding Unusual Items	-266.82	-253.25	-221.82	-166.16	-139.12	Upgrade
Merger & Restructuring Charges	-	-3	-	-	-	Upgrade
Gain (Loss) on Sale of Investments	8.08	10.65	-0.05	-2.91	-0.58	Upgrade
Pretax Income	-258.75	-245.6	-221.86	-169.07	-139.7	Upgrade
Net Income	-258.75	-245.6	-221.86	-169.07	-139.7	Upgrade
Net Income to Common	-258.75	-245.6	-221.86	-169.07	-139.7	Upgrade
Shares Outstanding (Basic)	95	84	68	63	55	Upgrade
Shares Outstanding (Diluted)	95	84	68	63	55	Upgrade
Shares Change (YoY)	12.85%	23.27%	7.77%	14.18%	13.00%	Upgrade
EPS (Basic)	-2.73	-2.92	-3.26	-2.67	-2.52	Upgrade
EPS (Diluted)	-2.73	-2.92	-3.26	-2.67	-2.52	Upgrade
Free Cash Flow	-215.59	-211.35	-186.5	-128.78	-95.25	Upgrade
Free Cash Flow Per Share	-2.27	-2.52	-2.74	-2.04	-1.72	Upgrade
EBITDA	-263.83	-249.56	-217.58	-160.88	-133.16	Upgrade
D&A For EBITDA	9.38	7.1	6.27	5.37	1.15	Upgrade
EBIT	-273.21	-256.66	-223.84	-166.25	-134.3	Upgrade

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q